NCT05587894: OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial
- State
- Under way
- Phase
- Phase 2
- People
- 256 planned
- Started
- 27 Apr 2023
- Primary completion
- 31 Dec 2026
- Arms
- Nirmatrelvir/r 5 days + remdesivir s.d
- Results
- None posted
- 20 Oct 2022: Trial registered
- 27 Apr 2023: Trial started